PHARMACEUTICAL INNOVATION IN EUROPE

The advent of new potential blockbusters in Europe is anticipated to position the pharmaceutical industry on a sustained growth pattern through 2022 (2015-2022 CAGR at 3.2%). While oncology is set to take the lion’s share in terms of growth, innovations have been emerging across several therapy areas.

Among the top 10 bestselling products in 2022 the crown is expected to move from Humira to Xarelto while five therapies will be addressing unmet needs in cancer. As the pharmaceutical pipeline continues to meet the demand for improved outcomes, question marks on the sustainability of the system as we know it continue to rise.

报告下载：

欧洲制药创新